CITRASATE C1125 2.14 G
MAGNESIUM CHLORIDE : 2.14 G CITRIC ACID : 6.91 G DEXTROSE : 49.5 G POTASSIUM CHLORIDE : 3.35 G SODIUM CHLORIDE : 263 G SODIUM ACETATE : 1.11 G CALCIUM CHLORIDE : 6.24 G · DIN 02366541 · CHIEF MEDICAL SUPPLIES LTD
Health Canada status: DORMANT
What is CITRASATE C1125?
CITRASATE C1125 2.14 G contains MAGNESIUM CHLORIDE : 2.14 G CITRIC ACID : 6.91 G DEXTROSE : 49.5 G POTASSIUM CHLORIDE : 3.35 G SODIUM CHLORIDE : 263 G SODIUM ACETATE : 1.11 G CALCIUM CHLORIDE : 6.24 G. It is listed in the Health Canada Drug Product Database under DIN 02366541, held by CHIEF MEDICAL SUPPLIES LTD, supplied as SOLUTION for HAEMODIALYSIS administration. Health Canada currently lists it as dormant, status dated 15-Jun-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02366541 |
|---|---|
| Brand name | CITRASATE C1125 |
| Generic / active ingredient | MAGNESIUM CHLORIDE : 2.14 G CITRIC ACID : 6.91 G DEXTROSE : 49.5 G POTASSIUM CHLORIDE : 3.35 G SODIUM CHLORIDE : 263 G SODIUM ACETATE : 1.11 G CALCIUM CHLORIDE : 6.24 G |
| Manufacturer | CHIEF MEDICAL SUPPLIES LTD |
| Strength | 2.14 G |
| Dosage form | SOLUTION |
| Route of administration | HAEMODIALYSIS |
| Schedule | Ethical |
| ATC code | B05ZA HEMODIALYTICS, CONCENTRATES |
| AHFS class | 40:34.00* ; See footnote |
| Biosimilar | No |
| Health Canada status | DORMANT |
| Status date | 15-Jun-2022 |
| Original market date | 2011-07-04 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code B05ZA HEMODIALYTICS, CONCENTRATES. 117 of 588 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACID CONCENTRATE 2156 | 10.1 G | SOLUTION | VANTIVE ULC | MARKETED | DIN 02239491 |
| ACID CONCENTRATE 2182 | 262.98 G | SOLUTION | VANTIVE ULC | MARKETED | DIN 02210835 |
| ACID CONCENTRATE A1221 | 3.35 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254344 |
| ACID CONCENTRATE A1222 | 263 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254336 |
| ACID CONCENTRATE A1223 | 9.92 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254328 |
| ACID CONCENTRATE A1224 | 263 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254301 |
| ACID CONCENTRATE A1225 | 263.0 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254298 |
| ACID CONCENTRATE A1226 | 49.5 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254255 |
| ACID CONCENTRATE A1227 | 8.27 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254247 |
| ACID CONCENTRATE A1228 | 49.5 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02533774 |
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.